Videos

Bluma Brenner, PhD, explains the driving factors behind the push for new antiretroviral drugs for HIV treatment.

Brian Woodfall, MD, shares his opinion on some of the biggest advancements in HIV treatment and prevention.

Paul Sax, MD, reacts to the ATLAS and FLAIR studies on long-acting injectable therapy.

Susan Swindells, MBBS, provides an overview of long-acting injectable cabotegravir + rilpivirine for clinicians.

Karin Bosh, PhD, explains why the opioid overdose death rate was higher in 2015 than in 2011 among people with HIV.

Julia Marcus, PhD, MPH, provides advice for health care systems looking to implement a model to identify potential PrEP candidates.

Ava Avalos, MD, details the effects of a dolutegravir-based regimen on pregnancy.

Paul Drain, MD, MPH, explains how point-of-care viral load testing was successful in providing rapid results to patients in a South African-based study.

Kavita Misra, PhD, MPH, explains how health care providers can help prevent PrEP resistance from growing by increasing screening for acute HIV infection.

Paul Sax, MD, details his research on integrase inhibitor-based regimens and weight gain.

Brad Hare, MD, explains how the findings of the DISCOVER study indicate that PrEP is no longer a one-size-fits-all situation.

Bluma Brenner, PhD, confesses that HIV "terrifies the hell" out of her, as it continues to build resistance against existing therapy regimens.

Laura Waters, MD, FRCP, an author on the Nature article on the reported HIV remission of the London Patient, explains why it is too soon to label the remission as a cure.

Paul Sax, MD, shares his take on news of the second person ever achieving long-term HIV remission.

Ava Avalos, MD, discusses the "encouraging" 12-month outcomes from the Botswana Beat Cohort study, which employs a dolutegravir-based regimen.

Paul Drain, MD, MPH, discusses the results of a study evaluating point-of-care viral load testing and discusses the advantages to implementation.

Paul Sax, MD, explains how he would demystify PrEP to clinicians who are not comfortable using HIV medications.

W. David Hardy, MD, adjunct professor of medicine in the Division of Infectious Disease at Johns Hopkins University, talks about the challenges of treating patients with HIV and comorbidities.

Paul Sax, MD, explains the lack of concrete progress in the curing of HIV.

W. David Hardy, MD, discusses long-acting injectable agents in the pipeline.

Ian Frank, MD, addresses reasons why some clinicians are not recommending PrEP to individuals who could benefit from the regimen.

Paul Edward Sax, MD, explains how one obstacle of HIV treatment and care is maintaining adherence.

W. David Hardy, MD, discusses the Undetectable Equals Untransmittable (U=U) movement.

Ian Frank, MD, discusses the future of HIV prevention and long-acting injectables.

Paul Sax, MD, discusses 2-drug approaches for treatment of HIV, including dolutegravir + lamivudine.

W. David Hardy, MD, discusses how important access to PrEP is for people at high risk of contracting HIV.

Ian Frank, MD discusses how younger individuals who do not take regular medication may struggle to adhere to the daily routine.

Paul Sax, MD, discusses treatments for HIV that are currently in development.